Skip to main content
. 2024 Jun 4;26(11):2084–2099. doi: 10.1093/neuonc/noae094

Figure 5.

Figure 5.

(A) Immunostainings demonstrate Ang-2 expression in CD31-positive brain microvessels exploited by panCK-positive metastasizing cancer cells in the human brain pre-metastatic niche (scale bar 50 µm). (B) Ratio of Ang-2/CD31 expression in tumor vessels in human brain metastases (BM) of different types of metastatic cancers (n = 191 patients Ang-2 data, one patient missing CD31 data). (C) Association of Ang-2/CD31 ratio and BM size. (D) Association of Ang-2/CD31 ratio and number of BM. (E) Kaplan–Meier survival curves of patients with low or high ratios of Ang-2/CD31 expression (median split) in metastatic brain lesions. Results of Log-rank test are shown. (F) Kaplan–Meier survival curves of combined Ki67 dichotomization (median split) and Ang-2/CD31 ratio dichotomization (median split) showing four groups illustrating low/low, high/high, high/low, and low/high expressors (total n = 189 due to single patients with missing data for CD31 and Ki67). Hierarchical cluster analyses of tumor area, positively labeled with antibodies against collagen I, CD31, and Ang-2. Kaplan–Meier survival curve of patients belonging to different stromal vascular clusters (H). Survival from date of BM surgery until last contact (H) are depicted. Throughout the figure, the numbers of the samples tested are indicated in parentheses. These vary due to partly missing clinical or experimental data.